MedMira Presents World's First OTC Rapid HIV Test to International Conference MiraCare(TM) Rapid HIV Test Shows 100% Agreement in Independent Evaluation HALIFAX, March 2 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ:MMIRF) the global market leader in rapid flow-through diagnostic technology, announced today that it had presented its MiraCare(TM) rapid, over-the-counter (OTC) test to participants of an international HIV diagnostics conference hosted by the United States Centers for Disease Control (CDC). The conference, entitled "HIV Diagnostics: New Developments and Challenges", was attended by HIV-diagnostic healthcare personnel from the private and public health sectors situated around the world. The conference focused on reevaluating the options for HIV diagnosis and confirmation with the availability of new HIV testing technologies, such as rapid HIV tests. During the conference, MedMira presented the results of an independent clinical evaluation of the MiraCare(TM) Rapid HIV Test which showed 100% agreement with traditional HIV testing methods. This performance evaluation was carried out using all types of blood analytes: serum, plasma, as well as venipuncture and fingerstick whole blood. "Our MiraCare(TM) Rapid HIV Test is one of the newest and greatest developments in today's global HIV diagnostic market. This conference provided an ideal forum to introduce our new OTC HIV test to the key individuals in the international healthcare community," said Hermes Chan, President and Chief Operating Officer of MedMira. Chan continued, "The MiraCare(TM) test offers a viable alternative to people who would otherwise not choose to be tested for HIV. Although the stigma associated with HIV testing has decreased substantially in recent years, many people still prefer the option of performing an HIV test in the privacy of their home. This has been proven by the marketing success of the MiraCare(TM) test in Hong Kong and Macao." The MiraCare(TM) Rapid HIV Test utilizes MedMira's world's fastest flow- through technology platform, at only 3-minutes. The speed and accuracy of the test, as demonstrated by the results of this most recent independent evaluation, reflect the value of this product to all levels of consumers (from physicians and clinicians to pharmacists and the general public) in comparison to traditional testing methods, which take days or weeks to provide test results. The MiraCare(TM) Rapid HIV Test is sold as a complete test package containing all required components and instructions for an individual to conduct the test quickly using a drop of fingerstick whole blood, with results in just 3 minutes. The MiraCare(TM) Rapid HIV Test is also available in a serum/plasma/venipuncture whole blood format for use by healthcare professionals. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- though rapid diagnostic tests for the clinical laboratory market. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(TM) G2 and MiraWell(TM) Rapid HIV Tests, respectively. For more information visit MedMira's website at http://www.medmira.com/. MedMira's Reveal(TM) G2 and MiraWell(TM) rapid HIV tests are currently used in clinical laboratories and hospitals where professional counseling and patient treatment are immediately available. MedMira markets its rapid tests worldwide in such countries as the United States, Canada, South Africa and China. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Beijing, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. DATASOURCE: MedMira Inc. CONTACT: Media Contact: Investor Relations, Dr. James Smith: (902) 450-1588 or e-mail:

Copyright